» Articles » PMID: 35171032

Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas Aeruginosa Virulence

Abstract

In the current scenario of antibiotic resistance magnification, new weapons against top nosocomial pathogens like Pseudomonas aeruginosa are urgently needed. The interplay between β-lactam resistance and virulence is considered a promising source of targets to be attacked by antivirulence therapies, and in this regard, we previously showed that a peptidoglycan recycling blockade dramatically attenuated the pathogenic power of P. aeruginosa strains hyperproducing the chromosomal β-lactamase AmpC. Here, we sought to ascertain whether this observation could be applicable to other β-lactamases. To do so, P. aeruginosa wild-type or peptidoglycan recycling-defective strains (Δ and Δ) harboring different cloned β-lactamases (transferable GES, VIM, and OXA types) were used to assess their virulence in Galleria mellonella larvae by determining 50% lethal doses (LDs). A mild yet significant LD increase was observed after peptidoglycan recycling disruption , whereas the expression of class A and B enzymes did not impact virulence. While the production of the narrow-spectrum class D OXA-2 entailed a slight attenuation, its extended-spectrum derivatives OXA-226 (W159R [bearing a change of W to R at position 159]), OXA-161 (N148D), and principally, OXA-539 (D149 duplication) were associated with outstanding virulence impairments, especially in recycling-defective backgrounds (with some LDs being >1,000-fold that of the wild type). Although their exact molecular bases remain to be deciphered, these results suggest that mutations affecting the catalytic center and, therefore, the hydrolytic spectrum of OXA-2-derived enzymes also drastically impact the pathogenic power of P. aeruginosa. This work provides new and relevant knowledge to the complex topic of the interplay between the production of β-lactamases and virulence that could be useful to build future therapeutic strategies against P. aeruginosa. Pseudomonas aeruginosa is one of the leading nosocomial pathogens whose growing resistance makes the development of therapeutic options extremely urgent. The resistance-virulence interplay has classically aroused researchers' interest as a source of therapeutic targets. In this regard, we describe a wide array of virulence attenuations associated with different transferable β-lactamases, among which the production of OXA-2-derived extended-spectrum β-lactamases stood out as a dramatic handicap for pathogenesis, likely as a side effect of mutations causing the expansion of their hydrolytic spectrums. Moreover, our results confirm the validity of disturbing peptidoglycan recycling as a weapon to attenuate P. aeruginosa virulence in class C and D β-lactamase production backgrounds. In the current scenario of dissemination of horizontally acquired β-lactamases, this work brings out new data on the complex interplay between the production of specific enzymes and virulence attenuation that, if complemented with the characterization of the underlying mechanisms, will likely be exploitable to develop future virulence-targeting antipseudomonal strategies.

Citing Articles

Refined methodology for quantifying virulence using .

Axline C, Kochan T, Nozick S, Ward T, Afzal T, Niki I Microbiol Spectr. 2024; 13(2):e0166624.

PMID: 39665556 PMC: 11792518. DOI: 10.1128/spectrum.01666-24.


Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.

Sendra E, Fernandez-Munoz A, Zamorano L, Oliver A, Horcajada J, Juan C Infection. 2024; 52(4):1235-1268.

PMID: 38954392 PMC: 11289218. DOI: 10.1007/s15010-024-02313-x.


NagZ modulates the virulence of by acting through the gene of unknown function, ECL_03795.

Yang X, Zeng J, Wang D, Zhou Q, Yu X, Wang Z Virulence. 2024; 15(1):2367652.

PMID: 38912723 PMC: 11197897. DOI: 10.1080/21505594.2024.2367652.


Transferable AmpCs in : interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications.

Barcelo I, Escobar-Salom M, Cabot G, Perello-Bauza P, Jordana-Lluch E, Taltavull B Antimicrob Agents Chemother. 2024; 68(5):e0131523.

PMID: 38517189 PMC: 11064642. DOI: 10.1128/aac.01315-23.


activity of human defensins HNP-1 and hBD-3 against multidrug-resistant ESKAPE Gram-negatives of clinical origin and selected peptidoglycan recycling-defective mutants.

Escobar-Salom M, Barcelo I, Rojo-Molinero E, Jordana-Lluch E, Cabot G, Oliver A Microbiol Spectr. 2024; 12(4):e0035824.

PMID: 38441982 PMC: 10986477. DOI: 10.1128/spectrum.00358-24.


References
1.
Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C . Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014; 58(6):3091-9. PMC: 4068469. DOI: 10.1128/AAC.02462-13. View

2.
Bragg R, Meyburgh C, Lee J, Coetzee M . Potential Treatment Options in a Post-antibiotic Era. Adv Exp Med Biol. 2018; 1052:51-61. DOI: 10.1007/978-981-10-7572-8_5. View

3.
Leonard D, Bonomo R, Powers R . Class D β-lactamases: a reappraisal after five decades. Acc Chem Res. 2013; 46(11):2407-15. PMC: 4018812. DOI: 10.1021/ar300327a. View

4.
Damblon C, Zhao G, Jamin M, LEDENT P, Dubus A, Vanhove M . Breakdown of the stereospecificity of DD-peptidases and beta-lactamases with thiolester substrates. Biochem J. 1995; 309 ( Pt 2):431-6. PMC: 1135750. DOI: 10.1042/bj3090431. View

5.
Aoki S, Hirakata Y, Kondoh A, Gotoh N, Yanagihara K, Miyazaki Y . Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo. Antimicrob Agents Chemother. 2004; 48(5):1876-8. PMC: 400588. DOI: 10.1128/AAC.48.5.1876-1878.2004. View